[Department of Error] Department of Error
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2016; 389: 255–65—In this Article, the adverse event grade was incorrect in the two patients in the safety analysis with immune-mediated hepatitis with atezolizumab; it should have read grade 4. The atezolizumab number at risk on figure 2A (ITT population) should read 363 on the atezolizumab arm.